Skip to main content
. Author manuscript; available in PMC: 2021 Mar 28.
Published in final edited form as: Oncogene. 2020 Sep 28;39(45):6935–6949. doi: 10.1038/s41388-020-01479-6

Figure 6: Characterization of AR-FL, AR-V7, vs. Total AR Knockout in LN-95 cells in vitro.

Figure 6:

a) Overview of the CRISPR-Cas9 approach used to knockout AR-FL and/or AR-V7 in LN-95 cells. b) Western blot documenting knockout of AR-FL, AR-V7, or both in multiple LN-95 clones. c) IHC (200X) staining of parental LN-5 cells expressing both AR-FL and AR-V7 vs. AR-negative PC-3 cells and the relevant AR-knockout clones. d) Immunoblot documenting nuclear localization of LN-95 cell clones expressing only AR-V7 expressing (i.e. AR-FL KO) clones. e) RNAseq-based analysis of AR-target genes in parental, AR-FL, AR-V7, and total AR KO clones. f) In vitro growth after 6 days of the parental LN-95 cells vs. AR-FL, AR-V7, and total AR KO clones in 10% CS-FBS media.